Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYBREL vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy
Prevention of pregnancy
One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life: 27 ± 8 hours; requires ~5 days to reach steady-state; clinical significance: missed doses lead to rapid loss of contraceptive efficacy.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Levonorgestrel: primarily metabolized via reduction, hydroxylation, and conjugation; CYP3A4 involvement. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation and sulfation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal: 50-60% as metabolites, ~20% as parent drug; fecal: 30-40%; biliary: 10-20%.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
99% bound to albumin and sex hormone-binding globulin (SHBG).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Vd: 1.7 ± 0.3 L/kg; indicates extensive tissue distribution (e.g., reproductive organs, liver).
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 88% (range 80-95%); first-pass metabolism reduces systemic exposure by ~12%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh class B and C hepatic impairment. Use with caution in Child-Pugh class A; monitor liver function.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Safety and efficacy not established in postmenarchal pediatric patients for oral contraception. Use same dosing as adults for appropriate indications.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for use in postmenopausal women; no age-specific data.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Thrombotic disorders and cardiovascular events (especially in smokers >35 years),Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Glucose intolerance,Hereditary angioedema,Chloasma,Ocular changes (e.g., retinal thrombosis) requiring discontinuation
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Renal or hepatic impairment,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,History of or current thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Active liver disease (e.g., acute viral hepatitis),Hypersensitivity to any component
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
No specific foods are known to interact with Lybrel. Grapefruit juice may slightly increase ethinyl estradiol levels but effect is not clinically significant. Avoid St. John's wort as it may reduce contraceptive efficacy.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Combined hormonal contraceptives (CHCs) like Lybrel (levonorgestrel/ethinyl estradiol) are contraindicated in pregnancy due to potential fetal harm. First trimester exposure is associated with a slightly increased risk of congenital anomalies, particularly cardiovascular and limb defects, though absolute risk is low. Second and third trimester exposure may lead to adverse outcomes including fetal growth restriction, preterm birth, and neonatal withdrawal symptoms. Data from observational studies suggest no major teratogenic risk at typical contraceptive doses, but use is not recommended once pregnancy is confirmed.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Small amounts of ethinyl estradiol and levonorgestrel are excreted in breast milk. The M/P ratio for ethinyl estradiol is approximately 0.05-0.1; for levonorgestrel, it is about 0.1-0.3. Combined hormonal contraceptives may reduce milk production and composition, especially in early postpartum period. Lybrel is not recommended during breastfeeding until weaning, or for at least 6 months postpartum if breastfeeding is established. Progestin-only contraceptives are preferred.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Lybrel is contraindicated in pregnancy; no dose adjustment is indicated as it should be discontinued immediately upon pregnancy diagnosis. Pharmacokinetic changes in pregnancy (e.g., increased clearance of ethinyl estradiol and levonorgestrel) are not relevant as the drug is not used therapeutically during pregnancy.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Lybrel is a continuous combined oral contraceptive (COC) containing levonorgestrel 90 mcg and ethinyl estradiol 20 mcg, designed to eliminate monthly withdrawal bleeding. It is taken daily without placebo pills. Breakthrough bleeding and spotting are common in the first 6–12 months. Patients should be counseled that amenorrhea may take up to a year to achieve. Lybrel does not protect against STIs. It is contraindicated in smokers over 35, hypertension (≥160/100 mm Hg), migraine with aura, and thromboembolic disorders. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) may reduce efficacy.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one pill every day at the same time, with or without food. There are no placebo pills, so you will take an active pill daily.,You may experience irregular bleeding or spotting, especially during the first 6–12 months. This is normal and usually decreases over time.,Do not expect a regular menstrual period. Most women will have no bleeding after one year of use.,If you miss pills, follow the package instructions. Missing pills increases the risk of pregnancy and may cause bleeding.,Use a backup method of contraception (like condoms) if you miss two or more pills or start a new pack late.,This medication does not protect against HIV or other sexually transmitted infections.,Tell your healthcare provider if you have new or severe headaches, chest pain, leg pain, vision changes, or jaundice.,Do not smoke while taking this medication, as smoking increases the risk of serious cardiovascular side effects.,Inform all healthcare providers that you are taking Lybrel, especially before surgery or blood tests.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYBREL vs ALYACEN 1/35, answered by our medical review team.
LYBREL is a Oral Contraceptive that works by Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYBREL and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYBREL is: One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYBREL and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYBREL is classified as Category C. Combined hormonal contraceptives (CHCs) like Lybrel (levonorgestrel/ethinyl estradiol) are contraindicated in pregnancy due to potential fetal harm. First trimester exposure is ass. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.